Ponesimod-d4

• Description :

  Ponesimod-d4 (ACT-128800-d4) is the deuterium labeled Ponesimod (HY-10569) [1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM) . Ponesimod can protect against lymphocyte-mediated tissue inflammation[2][3][4].

• Product Name Alternative :

  ACT-128800-d4

• UNSPSC :

  12352005

• Target :

  Isotope-Labeled Compounds; LPL Receptor

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  GPCR/G Protein; Others

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Others

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2C)/C(S/C1=C\C3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC

• Molecular Formula :

  C23H21D4ClN2O4S

• Molecular Weight :

  465.00

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported